We present the diagnostic and clinical course of the first multicenter case series of pediatric patients with autoimmune encephalitis associated with N-type voltage-gated calcium channel antibodies.
Methods:
Data from 2 university hospitals were retrospectively reviewed and records of 3 patients with autoimmune encephalitis associated with N-type voltage-gated calcium channel antibodies were evaluated.
Results:
The 3 pediatric patients (all female) had symptoms that spanned the clinical spectrum. All 3, however, had regression of expressive language and agitation. Neuroimaging in all 3 patients was normal; electroencephalographic (EEG) findings varied among the 3 patients. Positive titers against the N-type voltage-gated calcium channel antibody were found in their cerebrospinal fluid. Following administration of intravenous immunoglobulin, all 3 had improvement in their core presenting symptoms.
Conclusion:
Autoimmune encephalitis associated with N-type voltage-gated calcium channel antibodies in the pediatric population presents with a wide clinical spectrum, although expressive language delay and agitation seem to be common symptoms. Treatment with intravenous immunoglobulin improves core symptoms.
ZulianiLGrausFGiomettoBBienCVincentA. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83(6):638–645.
GableMSSheriffHDalmauJTilleyDHGlaserCA. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54(7):899–904.
LancasterEMartinez-HernandezEDalmauJ. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179–189.
6.
DeresinskiSGumboTSchönT. The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2013;57(12):iii–iv.
DalmauJGleichmanAJHughesEG. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098.
19.
CatterallWA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol. 2000;16(1):521–555.
20.
WilliamsMEBrustPFFeldmanDH. Structure and functional expression of an omega-conotoxin-sensitive human N-type calcium channel. Science. 1992;257(5068):389–396.
21.
KomuroHRakicP. Selective role of N-type calcium channels in neuronal migration. Science. 1992;257(5071):806–809.
22.
LipscombeDKongsamutSTsienRW. α-Adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N-type calcium-channel gating. Nature. 1989;340(6235):639–642.
23.
DooleyDJLuppAHerttingG. Inhibition of central neurotransmitter release by ω-conotoxin GVIA, a peptide modulator of the N-type voltage-sensitive calcium channel. Naunyn Schmiedebergs Arch Pharmacol. 1987;336(4):467–470.
24.
MochidaSShengZ-HBakerCKobayashiHCatterallWA. Inhibition of neurotransmission by peptides containing the synaptic protein interaction site of N-type Ca 2+ channels. Neuron. 1996;17(4):781–788.
HeyesSPrattWSReesE. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog Neurobiol. 2015;134:36–54.
31.
GroenJLAndradeARitzK. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum Mol Genet. 2014;24(4):987–993.
32.
OhmoriIOuchidaMMikiT. A CACNB4 mutation shows that altered Ca v 2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. Neurobiol Dis. 2008;32(3):349–354.
33.
Von BrevernMTaNShankarA. Migrainous vertigo: mutation analysis of the candidate genes CACNA1A, ATP1A2, SCN1A, and CACNB4. Headache. 2006;46(7):1136–1141.
34.
El FarOMarquèzeBLevequeC. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem. 1995;64(4):1696–1702.
35.
MotomuraMLangBJohnstonIPalaceJVincentANewsom-DavisJ. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurologic Sci. 1997;147(1):35–42.
36.
FinkelLKohS. N-type calcium channel antibody-mediated autoimmune encephalitis: an unlikely cause of a common presentation. Epilepsy Behav Case Rep. 2013;1:92–96.
37.
GrausFTitulaerMJBaluR. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
38.
WermelingDP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy. 2005;25(8):1084–1094.
39.
TwitchellWBrownSMackieK. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol. 1997;78(1):43–50.
40.
GeeNSBrownJPDissanayakeVUOffordJThurlowRWoodruffGN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the subunit of a calcium channel. J Biol Chem. 1996;271(10):5768–5776.
41.
LukyanetzEShkrylVKostyukP. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43(1):9–18.
42.
WangS-JHuangC-CHsuK-STsaiJ-JGeanP-W. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport. 1996;7(18):3037–3040.
